$319 million IPO Kyverna sees shares soar on first day of trading

Kyverna is one of the early companies looking to expand cell therapy from cancer into larger autoimmune disease patient populations.

Source: bizjournals.com Health Care:Biotechnology headlines - February 9, 2024 Category: Biotechnology Authors: Ron Leuty Source Type: news